Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Pipeline Review, H2 2018
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Pipeline Review, H2 2018
SUMMARY
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Neprilysin also known as membrane metallo-endopeptidase (MME) is an enzyme that is encoded by the MME gene. Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P and bradykinin. It degrades the amyloid beta peptide whose abnormal misfolding and aggregation in neural tissue has been a cause of Alzheimer's disease. Inhibition of neprilysin helps in treatment of Pain and hypertension.
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 4 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders and Ophthalmology which include indications Acute Heart Failure, Chronic Heart Failure, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Nephropathy, Hypertension, Pain, Alzheimer's Disease, Cancer Pain, Diastolic Heart Failure, Keratoconjunctivitis Sicca (Dry Eye), Migraine, Neuropathic Pain (Neuralgia), Ocular Pain (Eye Pain), Post-Operative Pain, Resistant Hypertension, Systolic Heart Failure and Traumatic Pain.
The latest report Neprilysin - Pipeline Review, H2 2018, outlays comprehensive information on the Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Neprilysin also known as membrane metallo-endopeptidase (MME) is an enzyme that is encoded by the MME gene. Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P and bradykinin. It degrades the amyloid beta peptide whose abnormal misfolding and aggregation in neural tissue has been a cause of Alzheimer's disease. Inhibition of neprilysin helps in treatment of Pain and hypertension.
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 4 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders and Ophthalmology which include indications Acute Heart Failure, Chronic Heart Failure, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Nephropathy, Hypertension, Pain, Alzheimer's Disease, Cancer Pain, Diastolic Heart Failure, Keratoconjunctivitis Sicca (Dry Eye), Migraine, Neuropathic Pain (Neuralgia), Ocular Pain (Eye Pain), Post-Operative Pain, Resistant Hypertension, Systolic Heart Failure and Traumatic Pain.
The latest report Neprilysin - Pipeline Review, H2 2018, outlays comprehensive information on the Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)
- The report reviews Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Overview
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Companies Involved in Therapeutics Development
Novartis AG
Pharmaleads SA
Theravance Biopharma Inc
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Drug Profiles
(sacubitril + valsartan) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LHW-090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-265 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-37 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Neprilysin for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STR-324 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-0714 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1439 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Dormant Products
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Discontinued Products
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Product Development Milestones
Featured News & Press Releases
Aug 25, 2018: Novartis announces new data that show Entresto (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
May 28, 2018: Novartis International: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto
Apr 25, 2018: Real-world Data Show that Entresto Lowered Healthcare Costs in Patients with Heart Failure with Reduced Ejection Fraction
Apr 19, 2018: Pharmaleads to Present Data on PL37 at BioTrinity 2018 in London
Apr 19, 2018: Pharmaleads to Present Data on PL265 at BioTrinity 2018 in London
Apr 16, 2018: Novartis Aannounces new analysis demonstrating Entresto Helped Preserve Kidney Function in Patients with Chronic Heart Failure, Especially those with Diabetes
Apr 04, 2018: Novartis announces JAMA Cardiology Publication of Data Showing Entresto Improves Physical and Social Activity in HFrEF Patients Versus Enalapril
Mar 13, 2018: First subject enrolled in Phase I clinical trial of its non-opioid analgesic STR-324
Nov 12, 2017: New Novartis Entresto real world evidence data shows beneficial impact on quality of life in people living with heart failure
Sep 19, 2017: New analysis shows Entresto improved physical and social activity in patients with HFrEF
Jun 29, 2017: Pharmaleads Reports Positive Phase I SAD Data with its Dual ENKephalinase Inhibitor PL265 for the Treatment of Neuropathic Pain
May 12, 2017: Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor, at the ARVO 2017 Annual Meeting
May 09, 2017: Novartis heart failure treatment Entresto (sacubitril/valsartan) now available to patients in Ontario through the public provincial drug plan
May 05, 2017: Pharmaleads to Present PL265 for Ocular Pain Results at the ARVO 2017 Annual Meeting in Baltimore
Mar 23, 2017: Novartis Pharmaceuticals Canada Announces Entresto now covered in Quebec
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Overview
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Companies Involved in Therapeutics Development
Novartis AG
Pharmaleads SA
Theravance Biopharma Inc
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Drug Profiles
(sacubitril + valsartan) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LHW-090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-265 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-37 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Neprilysin for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STR-324 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-0714 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1439 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Dormant Products
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Discontinued Products
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Product Development Milestones
Featured News & Press Releases
Aug 25, 2018: Novartis announces new data that show Entresto (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
May 28, 2018: Novartis International: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto
Apr 25, 2018: Real-world Data Show that Entresto Lowered Healthcare Costs in Patients with Heart Failure with Reduced Ejection Fraction
Apr 19, 2018: Pharmaleads to Present Data on PL37 at BioTrinity 2018 in London
Apr 19, 2018: Pharmaleads to Present Data on PL265 at BioTrinity 2018 in London
Apr 16, 2018: Novartis Aannounces new analysis demonstrating Entresto Helped Preserve Kidney Function in Patients with Chronic Heart Failure, Especially those with Diabetes
Apr 04, 2018: Novartis announces JAMA Cardiology Publication of Data Showing Entresto Improves Physical and Social Activity in HFrEF Patients Versus Enalapril
Mar 13, 2018: First subject enrolled in Phase I clinical trial of its non-opioid analgesic STR-324
Nov 12, 2017: New Novartis Entresto real world evidence data shows beneficial impact on quality of life in people living with heart failure
Sep 19, 2017: New analysis shows Entresto improved physical and social activity in patients with HFrEF
Jun 29, 2017: Pharmaleads Reports Positive Phase I SAD Data with its Dual ENKephalinase Inhibitor PL265 for the Treatment of Neuropathic Pain
May 12, 2017: Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor, at the ARVO 2017 Annual Meeting
May 09, 2017: Novartis heart failure treatment Entresto (sacubitril/valsartan) now available to patients in Ontario through the public provincial drug plan
May 05, 2017: Pharmaleads to Present PL265 for Ocular Pain Results at the ARVO 2017 Annual Meeting in Baltimore
Mar 23, 2017: Novartis Pharmaceuticals Canada Announces Entresto now covered in Quebec
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Pharmaleads SA, H2 2018
Pipeline by Theravance Biopharma Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Pharmaleads SA, H2 2018
Pipeline by Theravance Biopharma Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Novartis AG
Pharmaleads SA
Theravance Biopharma Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Novartis AG
Pharmaleads SA
Theravance Biopharma Inc
